The UMCCC High-Throughput Screening (HTS) Core is a new core which offers center investigators the opportunity to translate hypothesis-driven research into clinically relevant discoveries. In general these efforts focus on dissecting the cellular and molecular mechanisms of cancer through the application of chemical genomics strategies. The UMCCC-HTS Core provides access to compound libraries, screening services, expert consultation, and information sharing for researchers interested in HTS of small molecules, natural product extracts and/or siRNA genomes. The biological and chemical collections at the core are also available for cell profile screening, targeted biology approaches and structure-based molecular modeling. The Core also provides screening to several regional universities and has ongoing collaborations with a number of outside non-profit research Institutions. The core staff assist researchers with assay development, provide training in general HTS techniques, supervise screening campaigns on biomedical targets, manage assay results In a secure relational database and provide advice on counter and secondary screening. Within the HTS Core, medicinal chemistry resources are available for consultation on appropriate follow-up compounds and structure-activity relationship (SAR) analysis. The UMCCC-HTS Core also has an alliance with the Center for Computational Medicine end Bioinformatics (CCMB) to use bioinformatics tools (ConceptGen) for analysis of siRNA HTS results (Sautor et al., 2010). The Core can fully support UMCCC objectives to Identify small molecule probes, potential therapeutic leads and genomic pathways Implicated In malignant diseases, Cancer biology (and relevant genetic models) has been investigated using biochemical and cell-based assays and many of these are amenable to HTS technologies such as flow cytometry, high-content analysis, spectrophotometric detection and transcriptional reporter systems (Collins and Workman, 2006). siRNA HTS, using whole genome or selected subsets of genes, provides pathway analysis and mechanism-based Interrogation of specific genes responsible for human cancer processes. The core and its database of screening results can be used for Individual target-based drug discovery or to Investigate specific chemotypes that affect related targets. Thus, the UMCCC-HTS core is well-positioned to facilitate the discovery of chemical probes for identification and interrogation of cancer targets at the molecular level.

Public Health Relevance

This program funding for the HTS Core will provide University of Michigan scientists with the resources to rapidly test hundreds of thousands of chemicals and thousands of genes for their effects on cells, proteins and enzymes. These studies will provide a first step toward Identifying new drugs to treat cancer and the relevant pathways Involved cancer pathologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-25
Application #
8559912
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
25
Fiscal Year
2013
Total Cost
$111,771
Indirect Cost
$48,226
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Khoriaty, Rami; Hesketh, Geoffrey G; Bernard, Amélie et al. (2018) Functions of the COPII gene paralogs SEC23A and SEC23B are interchangeable in vivo. Proc Natl Acad Sci U S A 115:E7748-E7757
Katz, Steven J; Ward, Kevin C; Hamilton, Ann S et al. (2018) Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol 36:1218-1224
Ulintz, Peter J; Greenson, Joel K; Wu, Rong et al. (2018) Lymph Node Metastases in Colon Cancer Are Polyclonal. Clin Cancer Res 24:2214-2224
Qin, Tingting; Zhang, Yanxiao; Zarins, Katie R et al. (2018) Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort. Sci Rep 8:11458
Xu, Shilin; Aguilar, Angelo; Xu, Tianfeng et al. (2018) Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. Angew Chem Int Ed Engl 57:1601-1605
Crespo, Joel; Wu, Ke; Li, Wei et al. (2018) Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol 201:814-820
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865

Showing the most recent 10 out of 1493 publications